Bharat Biotech
Indian govt. should properly explain vaccine doses gap: Satyajit Rath

Immunologist Dr. Satyajit Rath and Newsclick’s Prabir Purkayastha talk about the Indian government’s decision to extend the interval between doses

COVID-19 vaccine: Who holds intellectual property rights?

Immunologist Dr. Satyajit Rath and Newsclick’s Prabir Purkayastha talk about the recent debates on the intellectual property rights on vaccines and the possibilities of mass immunization

Bill Gates, the white man’s burden and Modi government’s vaccine debacle

An incompetent, vainglorious leadership, combined with the right-wing belief in magical capitalism, has led to the disaster that India is now facing

The West is practicing vaccine apartheid on a global level

China and India are the only two major countries that have been willing to export vaccines while also vaccinating their own people. Meanwhile, to rich countries, the billions of dollars of vaccine market for Big Pharma far outweigh the benefits of saving millions of lives

Covaxin trials: What 81% “interim efficacy” means

Bharat Biotech has claimed in a press release that its Covid-19 vaccine candidate, Covaxin, showed 81% efficacy in the “first interim analysis” of phase-3 trials.

In India, pseudo-nationalism trumps science in vaccine clearance

The recent regulatory clearance given to an indigenous developed vaccine candidate in India is an example of vaccine nationalism at its worst and jettisoning of all the principles of an evidence-based, scientific approach

Vaccine rollout battle: First past the post may win major market share

India’s mass vaccination plans may fail if it does not hold open discussions on its plans with health professionals and the people

COVID-19 Vaccines: Moderna declares successful trial results after Pfizer

The new vaccine candidate by Moderna Inc, called mRNA-1273, has reportedly shown 94.5% efficacy against the SARS-CoV-2 in the phase III clinical trials

    × To Subscribe